Mesoblast reports 44 percent Ryoncil growth. Mesoblast stock falls 3.11 percent

Published on 10/24/2026 at 18:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bell Potter trims its target to AUD 4.40 on October 16, 2026. Mesoblast stock costs EUR 1.12 on October 24, 2026, down 3.11 percent versus Tradegate.

Operating update and annual meeting

Mesoblast reported 44 percent Ryoncil revenue growth on October 16, 2026.
Net operating cash spend improved 85 percent in the first fiscal quarter ended September 30, 2026.
Mesoblast stock costs EUR 1.12 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 3.11 percent below the Tradegate close.
Mesoblast scheduled its annual meeting for November 10, 2026.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast (AU000000MSB8) reported a 44 percent increase in Ryoncil net revenue to USD 28.00 million from USD 19.00 million in the first fiscal quarter ended September 30, 2026. The update, dated October 16, 2026, also showed an 85 percent improvement in net operating cash spend to USD 2.30 million from USD 14.90 million, according to Mesoblast. Mesoblast stock was trading at EUR 1.12 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 3.11 percent versus the Tradegate close of EUR 1.16 on October 23, 2026.

Ryoncil sales build commercial scale

The September quarter marked a growing commercial contribution from Ryoncil, Mesoblast's approved cell therapy for pediatric steroid-refractory acute graft-versus-host disease. Cash at September 30, 2026 stood at USD 99.00 million, while the company said September produced its highest monthly number of new patient starts.

The company also reported 54 onboarded treatment sites in the October 16 release. The figures remain preliminary and subject to customary closing and audit procedures, a qualification included in the company statement.

Price position on October 24

On Nasdaq, Mesoblast was last at USD 12.28 on October 23, 2026 at 4:00 p.m. ET. The same quote showed a 52-week range of USD 11.89 to USD 21.50, putting the latest Nasdaq price USD 0.39 above the low and USD 9.22 below the high. Market capitalization was USD 1.6 billion at that snapshot.

What comes next for Mesoblast?

Bell Potter retained its Buy rating and trimmed its price target to AUD 4.40 from AUD 4.45 in an assessment dated October 16, 2026, as reported by Motley Fool Australia. Mesoblast has scheduled its annual meeting for November 10, 2026, according to Simply Wall St.

Commercial progress meets execution risk

The operating update gives investors two distinct signals: Ryoncil sales rose sharply from the prior-year quarter, while cash spending fell by a larger percentage. The next test is whether patient starts and treatment-site expansion can sustain revenue growth beyond the seasonal softness noted in July and August. The Nasdaq price remains close to its 52-week low, while the Bell Potter target remains denominated in Australian dollars and is not directly comparable with the euro quotation.

Mesoblast stock was trading at EUR 1.12 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 3.11 percent below the Tradegate close of EUR 1.16 on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.